Gapping up
In reaction to strong earnings/guidance:
- CMG +13.4%, ORLY +12%, PENN +11.4%, BEAT +11.1%, UCTT +11%, PCMI +10.9%, AMD +9.5%, JAKK +9.5%, GNC +8.8%, DPZ +7.5%, FB +6.7%, CYS +6.6%, ALXN +6.5%, XLNX +6.1%, CETV +6.1%, ECHO +5.9%, SJW +5.8%, HZO +4.8%, RDN +4.8%, INTU +4.7%, (reports 6% increase in turbotax online units: raises full-year consumer group guidance range), TAL +4.5%, MMSI +4.3%, RRC +4.1%, PYPL +4.1%, LODE +4.1%, WPG +3.7%, CTXS +3.4%, MTH +3.3%, ALGT +3.2%, NS +3%, RS +2.8%, V +2.7%, AXTI +2.5%, BAX +2.2%, KNX +2.1%, RTN +2%, NOW +1.9%, WB +1.8%, EQT +1.7%, LVS +1.6%, F +1.6%, MCK +1.5%, (McKesson launches multi-year strategic growth initiative; reaffirms fiscal 2018 outlook and provides preliminary fiscal 2019 outlook; to acquire Medical Specialties Distributors), TRN +1.5%, COP +1.4%, VLO +1.2%, UPS +1.2%, SAVE +1%
M&A news:
- MATR +25.3% (NICE to acquire MATR for $2.70/share)
Select chip related names showing strength:
- MU +2.7%, INTC +2%, CY +2%, SMH +1.6%, SOXX +1.6%, ADI +0.6%, .
Other news:
- AZO +4% (following ORLY results)
- AAP +3.6% (following ORLY results)
- FMI +2.9% (FDA granted a Breakthrough Device designation for its new liquid biopsy assay)
- NVDA +2.5% (following AMD results)
- MSFT +1.5% (following AMD results)
- RESN +1.4% (continued strength)
- MA +1.3% (following Visa results)
- SNAP +1.2% (FB sympathy)
- KL +1.1% (reports drill intersections that provide 'significant' results at all three of its key exploration targets at Taylor mine), .
Analyst comments:
- TWTR +1.9% (upgraded to Outperform from Neutral at Macquarie)
- ANTM +0.9% (upgraded to Overweight from Neutral at JP Morgan)
- BA +0.8% (upgraded to Buy from Hold at Societe Generale)
Click here to read the full comment.
Portfolio Ticker Matches: AMD
This email was sent to you at: sgva@bloomberg.net. To ensure delivery to your Inbox and have images displayed properly, please add update@briefing.com to your Address Book or Safe Sender List.
Briefing.com sends these emails based on the preferences you set for your account. If you no longer wish to receive this email, unsubscribe here. To edit your email preferences, click here. Visit our Privacy Statement if you have any questions.
Briefing.com offers a wide range of premium services. Free trial requests can be made via our institutional sales or customer service departments.
401 N. Michigan Avenue Suite 1910 Chicago, IL 60611 | 800-752-3013
Copyright © 2018 Briefing.com, Inc. All rights reserved.
